Dr Mojtaba Tarin | Inorganic Chemistry | Best Researcher Award

postdoc researcher, Beijing Jiaotong University,

Dr. Mojtaba Tarin is a highly capable researcher with a strong foundation in inorganic chemistry, cancer nanomedicine, and targeted drug delivery. His academic trajectory, research productivity, technical skills, and teaching involvement position him as an emerging leader in biomedical nanotechnology and pharmaceutical chemistry. His hands-on experience with in vitro and in vivo models, synthesis of functional materials, and development of anti-cancer agents reflects both scientific excellence and translational relevance.

Publication Profile

Scopus

Academic Background:

Dr. Mojtaba Tarin earned his Ph.D. in Inorganic Chemistry from Ferdowsi University of Mashhad, Iran, in October 2023, graduating with a GPA of 18/20. His doctoral research focused on the “Design, Synthesis, and Investigation of Two Transport Systems of Functionalized Magnetic Mesoporous Silica Nanoparticles and Metal-Organic Frameworks (MOFs) for In Vitro and In Vivo Targeted Delivery of Elesclomol.” He holds a Master’s degree in Inorganic Chemistry from the Iranian Research Organization for Science and Technology (IROST), completed in 2015 with a GPA of 18.5/20, where he studied alkyl sulfosuccinate synthesis using heterogeneous catalysts. He completed his Bachelor’s degree at Shahrood University of Technology in 2011.

Professional Experience:

Dr. Tarin has been actively involved in academic and research roles. He served as a Teaching Assistant and Research Assistant at Ferdowsi University of Mashhad between 2018 and 2023. He supported courses like General Chemistry 1 and 2 while assisting with multiple advanced research projects related to pharmaceutical chemistry and drug delivery. He has also conducted and organized educational workshops on spectroscopy techniques, ChemDraw, and MTT cell toxicity testing, contributing significantly to hands-on student learning.

Honors and Recognitions:

Dr. Tarin holds two patents:

Synthesis of the Anti-Cancer Drug Elesclomol (Patent No. 104143, 2021)
Synthesis of Diethyl Sulfosuccinate Using Amberlyst-15 Catalyst (Patent No. 90267, 2016)

His peer-reviewed journal articles focus on targeted delivery of anti-cancer agents and nanotechnology-based therapies. His most recent works, under review and accepted, showcase pioneering research in Elesclomol delivery systems for prostate and colorectal cancer. He has also contributed to chemical synthesis research and co-authored studies on nickel complexes and surfactants.

Awards & Achievements:

Dr. Tarin holds two patents:

Synthesis of the Anti-Cancer Drug Elesclomol (Patent No. 104143, 2021)
Synthesis of Diethyl Sulfosuccinate Using Amberlyst-15 Catalyst (Patent No. 90267, 2016)

Publication :

- Tarin, M., Babaei, M., Eshghi, H., Matin, M. M., & Saljooghi, A. S. (2023). Targeted Delivery of Elesclomol Using a Magnetic Mesoporous Platform Improves Prostate Cancer Treatment Both In Vitro and In Vivo. Talanta. Manuscript ID: TAL-D-23-02570R1. (Accepted/In Press)
- Tarin, M., Babaie, M., Eshghi, H., Matin, M. M., & Saljooghi, A. S. (2023). Elesclomol, a Copper-Transporting Therapeutic Agent Targeting Mitochondria: From Discovery to Its Novel Applications. Journal of Translational Medicine, Manuscript ID: JTRM-D-23-03624 (R1), October 20, 2023.
- Tarin, M., Babaei, M., Eshghi, H., Matin, M. M., & Saljooghi, A. S. (2023). Targeted Delivery of Elesclomol Drug to Colorectal Cancer Cells Using a Porous Silicon Targeted Drug Delivery System with Magnetic Properties. Journal of Advanced Cancer Research, Manuscript ID: JACR-2305-2123 (R1), July 4, 2023.
- Moghadam, S. M. M., Salehi, S., Tarin, M., Azmudeh, S., Babaei, M., & Saljooghi, A. S. (2020). Synthesis, Identification, Theoretical Study, and Investigation of Cellular Toxicity Effects of Nickel (II) Complexes with Chelating Ligands 3-Hydroxyflavone, Deferiprone, and Maltol. Journal of Applied Research in Chemistry, September 22, 2020.
- Tarin, M., Moghadam, S. M. M., Salehi, S., & Saljooghi, A. S. (2019). Preparation of Sodium Dioctyl Sulfosuccinate Anionic Surfactant and Investigation of Catalytic Activity of Amberlyst-15. Journal of Applied Research in Chemistry, December 22, 2019.
- Salehi, S., Moghadam, S. M. M., Tarin, M., & Saljooghi, A. S. (2019). Pharmaceutical Nickel(II) Chelation Properties of 3-Hydroxyflaven, Deferiprone and Maltol Metal Chelators: A Density Functional Study. Physical Chemistry Research, DOI: 10.22036/pcr.2019.202156.1677, November 29, 2019.
- Tarin, M., Moghadam, S. M. M., Salehi, S., & Fateh, D. S. (2019). Dual Catalytic Activity of Amberlyst-15 in the Large-scale and Sustainable Synthesis of Dioctyl Sodium Sulfosuccinate (DOSS). Letters in Organic Chemistry, DOI: 10.2174/1570178616666191009105703, August 8, 2019.

conclusion:

Based on the evidence provided, Dr. Mojtaba Tarin is a highly suitable candidate for the Best Researcher Award, especially in the categories of Pharmaceutical Nanotechnology, Cancer Research, or Targeted Drug Delivery Systems. His work bridges fundamental chemistry with applied biomedical science, demonstrating both innovation and impact. With further international collaboration and funding experience, he could grow into a global scientific leader.

Mojtaba Tarin | Inorganic Chemistry | Best Researcher Award